OrbiMed Sells $39 Million Worth of Enliven Therapeutics Shares Amid Stock Rally
On June 22, 2026, OrbiMed Advisors sold approximately 860,123 shares in Enliven Therapeutics for around $39 million. The transaction reduced its indirect ownership stake but did not represent a full exit from the company. Enliven's stock has seen a significant rally of over 130% year-to-date.
Tickers: $ELVN